Ventas (NYSE:VTR) issued an update on its FY19 earnings guidance on Friday morning. The company provided earnings per share guidance of $3.80-3.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.84.

Shares of VTR stock opened at $67.83 on Monday. The firm’s fifty day simple moving average is $68.23. The company has a debt-to-equity ratio of 0.94, a current ratio of 0.67 and a quick ratio of 0.56. Ventas has a 1 year low of $51.80 and a 1 year high of $73.74. The company has a market cap of $24.02 billion, a PE ratio of 16.66, a price-to-earnings-growth ratio of 4.38 and a beta of 0.28.

Ventas (NYSE:VTR) last issued its earnings results on Friday, July 26th. The real estate investment trust reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.38). Ventas had a net margin of 13.34% and a return on equity of 4.78%. The business had revenue of $950.70 million for the quarter, compared to the consensus estimate of $931.16 million. During the same period in the previous year, the firm earned $0.46 EPS. The company’s revenue was up .9% compared to the same quarter last year. As a group, analysts forecast that Ventas will post 3.83 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, July 12th. Stockholders of record on Monday, July 1st were issued a $0.7925 dividend. The ex-dividend date was Friday, June 28th. This represents a $3.17 annualized dividend and a dividend yield of 4.67%. Ventas’s payout ratio is currently 77.89%.

A number of research analysts recently commented on VTR shares. Stifel Nicolaus set a $14.00 target price on Oasis Petroleum and gave the company a buy rating in a research note on Wednesday, June 19th. Mitsubishi UFJ Financial Group increased their target price on Ventas to $67.00 and gave the company a neutral rating in a research note on Wednesday, June 19th. ValuEngine raised Zynerba Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, May 17th. Royal Bank of Canada reduced their target price on from GBX 80 ($1.05) to GBX 75 ($0.98) and set an outperform rating on the stock in a research note on Thursday, June 20th. Finally, BMO Capital Markets restated a hold rating and set a $73.00 price target on shares of Ventas in a research report on Monday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $65.88.

In related news, Chairman Debra A. Cafaro sold 68,084 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $66.54, for a total value of $4,530,309.36. Following the completion of the transaction, the chairman now directly owns 805,835 shares of the company’s stock, valued at $53,620,260.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP T Richard Riney sold 29,702 shares of the stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $70.45, for a total transaction of $2,092,505.90. Following the completion of the transaction, the executive vice president now directly owns 163,488 shares of the company’s stock, valued at $11,517,729.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 165,866 shares of company stock valued at $11,323,058. Company insiders own 1.40% of the company’s stock.

Ventas Company Profile

Ventas, Inc, an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of approximately 1,200 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, university-based research and innovation centers, inpatient rehabilitation and long-term acute care facilities, and health systems.

Read More: New Google Finance Tool and Screening Stocks

Earnings History and Estimates for Ventas (NYSE:VTR)

Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.